AlphAIAlphAI — Financial news for AI agents
SEC EDGARJUL 82 min read$NGNE

Cvijic Christine Mikail sold $173K of NGNE

Cvijic Christine Mikail (President and CFO) sold 4,800 shares of Neurogene Inc. (NGNE) at an average of $36.12 ($36.02–$36.13, $0.17M total) across 2 trades over 2026-07-06 to 2026-07-07 under a Rule 10b5-1 trading plan.

Original reporting
SEC EDGAR · Cvijic Christine Mikail
Published Jul 8, 2026, 1:08 AM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Jul 8, 2026, 1:33 AM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
AlphAI market briefInsider activity
Primary signal
$NGNE
Neutral
high confidence
Mentioned
$NGNE
Relevance
3/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$NGNENeutralLow
01

Why it matters

The disclosure updates the record of insider ownership and may slightly influence sentiment, but it does not introduce new operating or financial information.

02

Market read

A routine, pre-arranged insider sale totaling ~$173.4K; more relevant for monitoring insider activity than for immediate fundamental repricing.

03

What to watch

The article provides only the sale details; it does not include any concurrent buys, option exercises, or changes in broader insider activity trends.

Relevance 3/10Novelty 3/10Timing: Filed after-hours on 2026-07-07; reflects sales executed 2026-07-06 to 2026-07-07.

Background

This is an SEC Form 4 insider transaction by Neurogene’s President and CFO, executed under a pre-arranged Rule 10b5-1 plan.

Company-level read

Ticker impact

$NGNENeutralHigh confidence
Context

Neurogene’s President and CFO sold 4,800 shares in open-market trades under a 10b5-1 plan, totaling about $173.4K.

Expected impact

Low likelihood of a sustained price move solely from this Form 4 sale; any impact is likely short-lived.

Evidence & confidence

The filing is a small, pre-arranged 10b5-1 open-market sale by an officer; it does not disclose new fundamentals, guidance, or transactions beyond the sale.

Market effects

Sector

No clear sector read-through; this is company-specific insider transaction data.

Regional

None indicated.

Global

None indicated.

Counterpoint

What could challenge this read

Even 10b5-1 sales can coincide with internal views on valuation or liquidity needs; traders may still front-run sentiment if selling accelerates.

Key entities

  • issuer
    Neurogene Inc.

    Subject of the Form 4 insider sale; ticker NGNE.

  • insider
    Cvijic Christine Mikail

    President and CFO; sold 4,800 shares in two open-market trades under a 10b5-1 plan.

Read at source← All news

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

NGNE insider trading history →

Related articles

OCT 27
$NGNEMedAI 8/10

Neurogene presents preclinical data on Rett syndrome therapy

Neurogene Inc. (NGNE) presented preclinical data on its NGN-401 gene therapy for Rett syndrome, showing durable protein expression and clinical improvements in trials. The therapy has received multiple FDA designations. NGN-401 is being evaluated in the Embolden registrational clinical trial, with no procedure-related adverse events reported in Phase 1/2 trials.

investing.com2 min
OCT 27
$NGNEHighAI 8/10

Rett trial participants showed improvement at a median of two months. It continued through 30 months.

Neurogene (NGNE) presented preclinical and clinical data on NGN-401, a gene therapy for Rett syndrome. The data showed rapid and durable expression of MECP2 in all brain tissues, challenging prior assumptions about AAV delivery methods. Clinical improvements were observed at a median of two months, continuing through 30 months. The company also presented data supporting the use of ICV administration for broad CNS biodistribution.

stocktitan.net2 min
OCT 8
$NGNEHigh

JPMorgan says this biotech stock can more than double following steep declines

JPMorgan initiated coverage of Neurogene with an overweight rating and a $60 price target, implying 132% upside. The bank's optimism is based on the company's gene therapy for Rett syndrome. Neurogene shares have fallen 32% over the past three months, partly due to broader biotech sector declines and softer Q2 results. The company plans to release new trial data in 2027, which JPMorgan sees as a potential catalyst.

cnbc.com1 min
OCT 8
$NGNEHigh

JPMorgan initiates Neurogene stock rating at Overweight on gene therapy potential

JPMorgan initiated coverage on Neurogene Inc. (NASDAQ: NGNE) with an Overweight rating and a $60.00 price target, citing potential in its gene therapy NGN-401 for Rett syndrome. The stock trades at $25.87, with analysts maintaining a Strong Buy consensus. Neurogene expects key data readouts in 2H27, with a market cap of $518 million and high volatility. Recent analyst adjustments include lowered price targets from H.C. Wainwright and Canaccord, both maintaining Buy ratings.

investing.com2 min
AUG 11
$NGNELow

Neurogene Reports Second Quarter 2026 Financial Results and Highlights Recent Updates

Neurogene Inc. (NGNE) filed an SEC Form 8-K — Results of Operations and Financial Condition. Neurogene Reports Second Quarter 2026 Financial Results and Highlights Recent Updates Data from Phase 1/2 trial of NGN-401 for Rett syndrome showed 100% of participants improved in CGI-I score and gained ≥1 developmental milestone, with an average of 4.7 milestones per participan

SEC EDGAR 8-K3 min